Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02057874
Other study ID # VICC GI 1343
Secondary ID
Status Terminated
Phase N/A
First received
Last updated
Start date February 2014
Est. completion date December 4, 2015

Study information

Verified date July 2018
Source Vanderbilt-Ingram Cancer Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This pilot clinical trial examines how well different imaging biomarkers acquired using 3-Telsa magnetic resonance imaging (MRI) methods perform in determining treatment response to transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma. Compared to conventional imaging, multi-parametric 3-Tesla MRI offers the ability to quantitatively measure tissue structural, functional, cellular, and molecular properties, providing a more robust, clinically relevant method for assessing cancer response to therapy.


Recruitment information / eligibility

Status Terminated
Enrollment 2
Est. completion date December 4, 2015
Est. primary completion date November 19, 2015
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Subjects must have signed an institutional review board (IRB)-approved informed consent document

- Subjects must have verified unresectable hepatocellular carcinoma (HCC), diagnosed on the basis of clinical and imaging criteria

- Subjects must be classified as TNM stage I, II, or III; alternatively, subjects may be classified as Barcelona Clinic Liver Cancer (BCLC) stage A or B

- Subjects must be scheduled to undergo transarterial chemoembolization (TACE)

- Subjects must have at least 1 lesion being targeted by TACE that is > 2 cm in the longest cross-sectional (axial plane) diameter

- Subjects must satisfy one of the following conditions pertaining to their eligibility to undergo orthotopic liver transplantation (OLT):

- HCC that is within Milan Criteria, i.e., TACE is indicated as a "bridge" to OLT (Group I); or

- HCC that is outside Milan Criteria, i.e., TACE is indicated as a means of "down-staging" into transplant eligibility (Group II)

Exclusion Criteria:

- Subjects who have received prior treatment for HCC (prior surgical procedures not related to HCC are allowed)

- Subjects who have undergone prior radioembolization

- Subjects with a central venous line

- Subjects who have any type of biomedical implant, device and/or ferromagnetic material that can be displaced, perturbed, or otherwise malfunction due to mechanical, electronic, or magnetic means; these items may include:

- Metallic fragments or shrapnel (such as from war wounds)

- Cerebral aneurysm clips, biopsy marker clips

- Vascular access ports (as are used with intravenous chemotherapy)

- Cochlear implants, pacemakers, neurostimulators, biostimulators, and electronic infusion pumps **Implanted materials other than those verified as being rated "magnetic resonance [MR] Safe" or "MR Conditional 6" will not be allowed on study

- Creatinine >= 1.5 times upper limit of normal

- Estimated glomerular filtration rate (eGFR) < 30 mL/min

- Subjects who are pregnant or nursing

- Subjects who have had past allergic or other adverse reactions to intravenous injection of Magnevist® (gadopentetate dimeglumine) or other gadolinium-containing contrast agents

- Subjects who exhibit noticeable anxiety, claustrophobia, or vertigo when moved into the scanner

- Subjects incapable of giving informed written consent, for the following reasons:

- Inability to adhere to the experimental protocols for any reason

- Inability to communicate with the research team

- Mental disability, altered mental status, confusion, or psychiatric disorders

- Prisoners or others susceptible to coercion

Study Design


Related Conditions & MeSH terms

  • Adult Primary Hepatocellular Carcinoma
  • Advanced Adult Primary Liver Cancer
  • Carcinoma
  • Carcinoma, Hepatocellular
  • Liver Neoplasms
  • Localized Resectable Adult Primary Liver Cancer
  • Localized Unresectable Adult Primary Liver Cancer
  • Stage A Adult Primary Liver Cancer (BCLC)
  • Stage B Adult Primary Liver Cancer (BCLC)

Intervention

Device:
3 Tesla Magnetic Resonance Imaging
3T MRI consists of a series of radiofrequency (RF) pulse sequences optimized for acquiring CEST-, MT-, DW-, and DCE-MRI data in one seamless imaging examination. For DCE, MR contrast agent will be intravenously administered.
Drug:
Magnevist® (Intravenous (IV) administration of MRI contrast agent)
For the acquisition of DCE-MR data, the FDA-approved contrast agent Magnevist® (gadopentetate dimeglumine, 0.1 mmol/kg) will be delivered intravenously by the MR technologist at a rate of 2 mL/sec (followed by a saline flush) via a power injector after the acquisition of a set of baseline dynamic scans. The entire sequence lasts approximately 8 minutes.

Locations

Country Name City State
United States Vanderbilt-Ingram Cancer Center Nashville Tennessee

Sponsors (2)

Lead Sponsor Collaborator
Vanderbilt-Ingram Cancer Center National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Correlation of Changes in Imaging Biomarkers (Ktrans, ADC, MTR, and APTasym) as Measured by DCE-, DW-, MT-, and CEST-MRI at 3 Tesla, Respectively, With Changes in Tumor Volume (mRECIST). The following will be longitudinally measured using 3 Tesla (3T) magnetic resonance imaging (MRI) prior to transarterial chemoembolization (TACE) and 2-4, 4-8, and 12 weeks following TACE: 1) the volume transfer coefficient (Ktrans), measured by dynamic contrast-enhanced (DCE) MRI; 2) the apparent diffusion coefficient (ADC), measured by diffusion-weighted (DW) MRI; 3) the magnetization transfer ratio (MTR), measured by magnetization transfer (MT) MRI; and 4) the amide proton transfer asymmetry (APTasym), measured by chemical exchange saturation transfer (CEST) MRI. We will use a general linear model (GLM) approach to measure the association between changes in each of the above imaging metrics (relative to pretreatment baseline) and changes in tumor volume (according to standard-of-care modified RECIST) at 3 or 6 month follow-up, accounting for the effect of potential confounders, e.g., age and size of the tumor at baseline. Baseline to up to 12 weeks post-TACE
Secondary Correlation of Changes in Ktrans, ADC, MTR, and APTasym (Measured by DCE-, DW-, MT-, and CEST-MRI at 3 Tesla, Respectively) With Time-to-progression (TTP). Proportional hazard model will be employed to assess the ability of the longitudinal change (relative to pretreatment baseline) in each of the 3T MR imaging metrics (Ktrans, ADC, MTR, and APTasym) to predict patient survival outcomes, time-to-progression (TTP) and progression-free survival (PFS) as well as overall survival (OS). The calibration of prediction will be validated by computing the difference between predicted survival and Kaplan-Meier survival estimates at a fixed time, which estimates the over-optimism of the difference using bootstrapping. Baseline to up to 6 months post-TACE
Secondary Correlation of Changes in Ktrans, ADC, MTR, and APTasym (Measured by DCE-, DW-, MT-, and CEST-MRI at 3 Tesla, Respectively) With Changes in the Ratio of Viable-to-necrotic Tumor Volume Longitudinal changes in 3T MRI-derived measures and the change in the ratio of viable vs. necrotic tumor will be assessed by using a GLM approach in which the underlying temporal correlation can be modeled via an autoregressive order one (AR(1)) structure, validated by computing Akaike Information Criterion (AIC) against the other common structures, e.g., unstructured and constant correlation. Baseline to up to 12 weeks post-TACE
Secondary Correlation of Ktrans, ADC, MTR, and APTasym (Measured by DCE-, DW-, MT-, and CEST-MRI at 3 Tesla, Respectively) With Pathological Response Within Explanted Tissue Following Orthotopic Liver Transplant (OLT) Histopathological features on explanted livers following OLT, including percentage necrosis and cellular density as determined by hematoxylin and eosin staining, as well as the extent of fibrosis as determined by collagen staining, will be assessed for correspondence with findings on ex vivo 3T MRI. Subset of patients undergoing OLT: within 12 hours following surgery
Secondary Correlation of Changes in Ktrans, ADC, MTR, and APTasym (Measured by DCE-, DW-, MT-, and CEST-MRI at 3 Tesla, Respectively) With Overall Survival (OS) Proportional hazard model will be employed to assess the ability of the longitudinal change (relative to pretreatment baseline) in each of the 3T MR imaging metrics (Ktrans, ADC, MTR, and APTasym) to predict patient survival outcomes, time-to-progression (TTP) and progression-free survival (PFS) as well as overall survival (OS). The calibration of prediction will be validated by computing the difference between predicted survival and Kaplan-Meier survival estimates at a fixed time, which estimates the over-optimism of the difference using bootstrapping. Baseline to up to 6 months post-TACE
See also
  Status Clinical Trial Phase
Terminated NCT00787787 - Sunitinib Malate and Capecitabine in Treating Patients With Unresectable or Metastatic Liver Cancer Phase 2
Completed NCT00052364 - Oxaliplatin in Treating Patients With Liver Cancer Phase 2
Completed NCT01229111 - Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary Cancers Phase 2
Completed NCT00107536 - Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer Phase 2
Completed NCT02072356 - Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot be Removed by Surgery Early Phase 1
Completed NCT00604721 - Selumetinib in Treating Patients With Locally Advanced or Metastatic Liver Cancer Phase 2
Completed NCT00101036 - Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By Surgery Phase 2
Completed NCT00028496 - Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer Phase 1
Completed NCT01766219 - CPI-613 in Treating Patients With Advanced or Metastatic Bile Duct Cancer That Cannot Be Removed By Surgery Phase 1/Phase 2
Terminated NCT00427973 - AZD2171 in Treating Patients With Locally Advanced Unresectable or Metastatic Liver Cancer Phase 2
Completed NCT00321594 - Belinostat in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery Phase 1/Phase 2
Terminated NCT00087191 - EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer N/A
Completed NCT00006016 - Thalidomide and Chemoembolization With Doxorubicin in Treating Patients With Liver Cancer That Cannot be Removed by Surgery Phase 2
Completed NCT01643499 - Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies Phase 1
Completed NCT00639509 - IMC-A12 in Treating Patients With Advanced Liver Cancer Phase 2
Completed NCT00083226 - Doxorubicin and Bortezomib in Treating Patients With Liver Cancer Phase 2
Completed NCT00033462 - Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder Cancer Phase 2
Completed NCT01666756 - Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer Phase 1
Active, not recruiting NCT02119065 - Pilot Study to Assess Lung Shunting of Yttrium-90 Microspheres Using PET/CT
Recruiting NCT02557503 - Hepatic Arterial Infusion of Oxaliplatin and Fluorouracil Treatment of Advanced Primary Liver Cancer After TACE Phase 4